Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson's disease where the pathophysiology led almost immediately to th...
Saved in:
| Published in: | Frontiers in neuroscience 2016-11, Vol.10, p.541-541 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | eng |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| recordid |
cdi_doaj_primary_oai_doaj_org_article_ca03d10c8f154678a9908f3f996bd1dd |
|---|---|
| title |
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases |
| format |
Article |
| creator |
Di Giovanni, Giuseppe Svob Strac, Dubravka Sole, Montse Unzeta, Mercedes Tipton, Keith F Mück-Šeler, Dorotea Bolea, Irene Della Corte, Laura Nikolac Perkovic, Matea Pivac, Nela Smolders, Ilse J Stasiak, Anna Fogel, Wieslawa A De Deurwaerdère, Philippe |
| subjects |
Addiction antidepressant Antidepressants antiparkinsonian treatments Cognitive ability Disease Dopamine Drug Addition Epilepsy Excitability Mental depression Mental disorders Monoamine Oxidase Inhibitors Monoamines Mood Movement disorders Neurodegenerative Diseases Neuroleptics Neurological diseases Neuroscience Parkinson's disease Pathophysiology Schizophrenia Side effects Stroke |
| ispartof |
Frontiers in neuroscience, 2016-11, Vol.10, p.541-541 |
| description |
The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson's disease where the pathophysiology led almost immediately to the introduction of dopamine restoring agents. Extensive neuropharmacological studies first showed that the primary target of antipsychotics, antidepressants, and anxiolytic drugs were specific components of the monoaminergic systems. Later, some dramatic side effects associated with older medicines were shown to disappear with new chemical compounds targeting the origin of the therapeutic benefit more specifically. The increased knowledge regarding the function and interaction of the monoaminergic systems in the brain resulting from
neurochemical and neurophysiological studies indicated new monoaminergic targets that could achieve the efficacy of the older medicines with fewer side-effects. Yet, this accumulated knowledge regarding monoamines did not produce valuable strategies for diseases where no monoaminergic drug has been shown to be effective. Here, we emphasize the new therapeutic and monoaminergic-based strategies for the treatment of psychiatric diseases. We will consider three main groups of diseases, based on the evidence of monoamines involvement (schizophrenia, depression, obesity), the identification of monoamines in the diseases processes (Parkinson's disease, addiction) and the prospect of the involvement of monoaminergic mechanisms (epilepsy, Alzheimer's disease, stroke). In most cases, the clinically available monoaminergic drugs induce widespread modifications of amine tone or excitability through neurobiological networks and exemplify the overlap between therapeutic approaches to psychiatric and neurological conditions. More recent developments that have resulted in improved drug specificity and responses will be discussed in this review. |
| language |
eng |
| source |
Publicly Available Content Database; PubMed Central |
| identifier |
ISSN: 1662-4548 |
| fulltext |
fulltext |
| issn |
1662-4548 1662-453X 1662-453X |
| url |
http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-05-26T22%3A02%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Monoaminergic%20and%20Histaminergic%20Strategies%20and%20Treatments%20in%20Brain%20Diseases&rft.jtitle=Frontiers%20in%20neuroscience&rft.au=Di%20Giovanni,%20Giuseppe&rft.date=2016-11-24&rft.volume=10&rft.spage=541&rft.epage=541&rft.pages=541-541&rft.issn=1662-4548&rft.eissn=1662-453X&rft_id=info:doi/10.3389/fnins.2016.00541&rft_dat=%3Cproquest_doaj_%3E1847893740%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c556t-310827eeb9fa8a63eb0c72cb0e4647e02bd93987cdfb051e25edc211637170593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2305538985&rft_id=info:pmid/27932945 |
| container_title |
Frontiers in neuroscience |
| container_volume |
10 |
| container_issue |
|
| container_start_page |
541 |
| container_end_page |
541 |
| fullrecord |
<record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ca03d10c8f154678a9908f3f996bd1dd</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ca03d10c8f154678a9908f3f996bd1dd</doaj_id><sourcerecordid>1847893740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c556t-310827eeb9fa8a63eb0c72cb0e4647e02bd93987cdfb051e25edc211637170593</originalsourceid><addsrcrecordid>eNpdkU1vEzEQhlcIREvhzglF4sIlYfxtX5CgfLSiiANF4mZ57dngaNcu9gaJf4-TlEC52NbMO-_M-Om6pwRWjGnzckgx1RUFIlcAgpN73SmRki65YN_uH99cn3SPat0ASKo5fdidUGUYNVycdh8_5ZTdFBOWdfQLl8LiItb5b-TLXNyM64h1n7wu6OYJ01wXMS3eFNfOt7Giq1gfdw8GN1Z8cnufdV_fv7s-v1heff5wef76aumFkPOSEdBUIfZmcNpJhj14RX0PyCVXCLQPhhmtfBh6EASpwOApIZIpokAYdtZdHnxDdht7U-Lkyi-bXbT7QC5r68oc_YjWO2CBgNcDEVwq7YwBPbDBGNkHEkLzenXwutn2U-vTNituvGN6N5Pid7vOP60glFC-G-bFrUHJP7ZYZzvF6nEcXcK8rZZorrRhikOTPv9PusnbktpXWcpAiEZUi6aCg8qXXGvB4TgMAbujbvfU7Y663VNvJc_-XeJY8Acz-w3DwKls</addsrcrecordid><sourcetype>Open Website</sourcetype><isCDI>true</isCDI><recordtype>article</recordtype><pqid>2305538985</pqid></control><display><type>article</type><title>Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Di Giovanni, Giuseppe ; Svob Strac, Dubravka ; Sole, Montse ; Unzeta, Mercedes ; Tipton, Keith F ; Mück-Šeler, Dorotea ; Bolea, Irene ; Della Corte, Laura ; Nikolac Perkovic, Matea ; Pivac, Nela ; Smolders, Ilse J ; Stasiak, Anna ; Fogel, Wieslawa A ; De Deurwaerdère, Philippe</creator><creatorcontrib>Di Giovanni, Giuseppe ; Svob Strac, Dubravka ; Sole, Montse ; Unzeta, Mercedes ; Tipton, Keith F ; Mück-Šeler, Dorotea ; Bolea, Irene ; Della Corte, Laura ; Nikolac Perkovic, Matea ; Pivac, Nela ; Smolders, Ilse J ; Stasiak, Anna ; Fogel, Wieslawa A ; De Deurwaerdère, Philippe</creatorcontrib><description>The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson's disease where the pathophysiology led almost immediately to the introduction of dopamine restoring agents. Extensive neuropharmacological studies first showed that the primary target of antipsychotics, antidepressants, and anxiolytic drugs were specific components of the monoaminergic systems. Later, some dramatic side effects associated with older medicines were shown to disappear with new chemical compounds targeting the origin of the therapeutic benefit more specifically. The increased knowledge regarding the function and interaction of the monoaminergic systems in the brain resulting from
neurochemical and neurophysiological studies indicated new monoaminergic targets that could achieve the efficacy of the older medicines with fewer side-effects. Yet, this accumulated knowledge regarding monoamines did not produce valuable strategies for diseases where no monoaminergic drug has been shown to be effective. Here, we emphasize the new therapeutic and monoaminergic-based strategies for the treatment of psychiatric diseases. We will consider three main groups of diseases, based on the evidence of monoamines involvement (schizophrenia, depression, obesity), the identification of monoamines in the diseases processes (Parkinson's disease, addiction) and the prospect of the involvement of monoaminergic mechanisms (epilepsy, Alzheimer's disease, stroke). In most cases, the clinically available monoaminergic drugs induce widespread modifications of amine tone or excitability through neurobiological networks and exemplify the overlap between therapeutic approaches to psychiatric and neurological conditions. More recent developments that have resulted in improved drug specificity and responses will be discussed in this review.</description><identifier>ISSN: 1662-4548</identifier><identifier>ISSN: 1662-453X</identifier><identifier>EISSN: 1662-453X</identifier><identifier>DOI: 10.3389/fnins.2016.00541</identifier><identifier>PMID: 27932945</identifier><language>eng</language><publisher>Switzerland: Frontiers Research Foundation</publisher><subject>Addiction ; antidepressant ; Antidepressants ; antiparkinsonian treatments ; Cognitive ability ; Disease ; Dopamine ; Drug Addition ; Epilepsy ; Excitability ; Mental depression ; Mental disorders ; Monoamine Oxidase Inhibitors ; Monoamines ; Mood ; Movement disorders ; Neurodegenerative Diseases ; Neuroleptics ; Neurological diseases ; Neuroscience ; Parkinson's disease ; Pathophysiology ; Schizophrenia ; Side effects ; Stroke</subject><ispartof>Frontiers in neuroscience, 2016-11, Vol.10, p.541-541</ispartof><rights>2016. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2016 Di Giovanni, Svob Strac, Sole, Unzeta, Tipton, Mück-Šeler, Bolea, Della Corte, Nikolac Perkovic, Pivac, Smolders, Stasiak, Fogel and De Deurwaerdère. 2016 Di Giovanni, Svob Strac, Sole, Unzeta, Tipton, Mück-Šeler, Bolea, Della Corte, Nikolac Perkovic, Pivac, Smolders, Stasiak, Fogel and De Deurwaerdère</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c556t-310827eeb9fa8a63eb0c72cb0e4647e02bd93987cdfb051e25edc211637170593</citedby><cites>FETCH-LOGICAL-c556t-310827eeb9fa8a63eb0c72cb0e4647e02bd93987cdfb051e25edc211637170593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2305538985/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2305538985?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,315,734,787,791,892,25799,27985,27986,37077,37078,44955,54176,54178,76120</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27932945$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Giovanni, Giuseppe</creatorcontrib><creatorcontrib>Svob Strac, Dubravka</creatorcontrib><creatorcontrib>Sole, Montse</creatorcontrib><creatorcontrib>Unzeta, Mercedes</creatorcontrib><creatorcontrib>Tipton, Keith F</creatorcontrib><creatorcontrib>Mück-Šeler, Dorotea</creatorcontrib><creatorcontrib>Bolea, Irene</creatorcontrib><creatorcontrib>Della Corte, Laura</creatorcontrib><creatorcontrib>Nikolac Perkovic, Matea</creatorcontrib><creatorcontrib>Pivac, Nela</creatorcontrib><creatorcontrib>Smolders, Ilse J</creatorcontrib><creatorcontrib>Stasiak, Anna</creatorcontrib><creatorcontrib>Fogel, Wieslawa A</creatorcontrib><creatorcontrib>De Deurwaerdère, Philippe</creatorcontrib><title>Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases</title><title>Frontiers in neuroscience</title><addtitle>Front Neurosci</addtitle><description>The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson's disease where the pathophysiology led almost immediately to the introduction of dopamine restoring agents. Extensive neuropharmacological studies first showed that the primary target of antipsychotics, antidepressants, and anxiolytic drugs were specific components of the monoaminergic systems. Later, some dramatic side effects associated with older medicines were shown to disappear with new chemical compounds targeting the origin of the therapeutic benefit more specifically. The increased knowledge regarding the function and interaction of the monoaminergic systems in the brain resulting from
neurochemical and neurophysiological studies indicated new monoaminergic targets that could achieve the efficacy of the older medicines with fewer side-effects. Yet, this accumulated knowledge regarding monoamines did not produce valuable strategies for diseases where no monoaminergic drug has been shown to be effective. Here, we emphasize the new therapeutic and monoaminergic-based strategies for the treatment of psychiatric diseases. We will consider three main groups of diseases, based on the evidence of monoamines involvement (schizophrenia, depression, obesity), the identification of monoamines in the diseases processes (Parkinson's disease, addiction) and the prospect of the involvement of monoaminergic mechanisms (epilepsy, Alzheimer's disease, stroke). In most cases, the clinically available monoaminergic drugs induce widespread modifications of amine tone or excitability through neurobiological networks and exemplify the overlap between therapeutic approaches to psychiatric and neurological conditions. More recent developments that have resulted in improved drug specificity and responses will be discussed in this review.</description><subject>Addiction</subject><subject>antidepressant</subject><subject>Antidepressants</subject><subject>antiparkinsonian treatments</subject><subject>Cognitive ability</subject><subject>Disease</subject><subject>Dopamine</subject><subject>Drug Addition</subject><subject>Epilepsy</subject><subject>Excitability</subject><subject>Mental depression</subject><subject>Mental disorders</subject><subject>Monoamine Oxidase Inhibitors</subject><subject>Monoamines</subject><subject>Mood</subject><subject>Movement disorders</subject><subject>Neurodegenerative Diseases</subject><subject>Neuroleptics</subject><subject>Neurological diseases</subject><subject>Neuroscience</subject><subject>Parkinson's disease</subject><subject>Pathophysiology</subject><subject>Schizophrenia</subject><subject>Side effects</subject><subject>Stroke</subject><issn>1662-4548</issn><issn>1662-453X</issn><issn>1662-453X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkU1vEzEQhlcIREvhzglF4sIlYfxtX5CgfLSiiANF4mZ57dngaNcu9gaJf4-TlEC52NbMO-_M-Om6pwRWjGnzckgx1RUFIlcAgpN73SmRki65YN_uH99cn3SPat0ASKo5fdidUGUYNVycdh8_5ZTdFBOWdfQLl8LiItb5b-TLXNyM64h1n7wu6OYJ01wXMS3eFNfOt7Giq1gfdw8GN1Z8cnufdV_fv7s-v1heff5wef76aumFkPOSEdBUIfZmcNpJhj14RX0PyCVXCLQPhhmtfBh6EASpwOApIZIpokAYdtZdHnxDdht7U-Lkyi-bXbT7QC5r68oc_YjWO2CBgNcDEVwq7YwBPbDBGNkHEkLzenXwutn2U-vTNituvGN6N5Pid7vOP60glFC-G-bFrUHJP7ZYZzvF6nEcXcK8rZZorrRhikOTPv9PusnbktpXWcpAiEZUi6aCg8qXXGvB4TgMAbujbvfU7Y663VNvJc_-XeJY8Acz-w3DwKls</recordid><startdate>20161124</startdate><enddate>20161124</enddate><creator>Di Giovanni, Giuseppe</creator><creator>Svob Strac, Dubravka</creator><creator>Sole, Montse</creator><creator>Unzeta, Mercedes</creator><creator>Tipton, Keith F</creator><creator>Mück-Šeler, Dorotea</creator><creator>Bolea, Irene</creator><creator>Della Corte, Laura</creator><creator>Nikolac Perkovic, Matea</creator><creator>Pivac, Nela</creator><creator>Smolders, Ilse J</creator><creator>Stasiak, Anna</creator><creator>Fogel, Wieslawa A</creator><creator>De Deurwaerdère, Philippe</creator><general>Frontiers Research Foundation</general><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20161124</creationdate><title>Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases</title><author>Di Giovanni, Giuseppe ; Svob Strac, Dubravka ; Sole, Montse ; Unzeta, Mercedes ; Tipton, Keith F ; Mück-Šeler, Dorotea ; Bolea, Irene ; Della Corte, Laura ; Nikolac Perkovic, Matea ; Pivac, Nela ; Smolders, Ilse J ; Stasiak, Anna ; Fogel, Wieslawa A ; De Deurwaerdère, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c556t-310827eeb9fa8a63eb0c72cb0e4647e02bd93987cdfb051e25edc211637170593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Addiction</topic><topic>antidepressant</topic><topic>Antidepressants</topic><topic>antiparkinsonian treatments</topic><topic>Cognitive ability</topic><topic>Disease</topic><topic>Dopamine</topic><topic>Drug Addition</topic><topic>Epilepsy</topic><topic>Excitability</topic><topic>Mental depression</topic><topic>Mental disorders</topic><topic>Monoamine Oxidase Inhibitors</topic><topic>Monoamines</topic><topic>Mood</topic><topic>Movement disorders</topic><topic>Neurodegenerative Diseases</topic><topic>Neuroleptics</topic><topic>Neurological diseases</topic><topic>Neuroscience</topic><topic>Parkinson's disease</topic><topic>Pathophysiology</topic><topic>Schizophrenia</topic><topic>Side effects</topic><topic>Stroke</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Giovanni, Giuseppe</creatorcontrib><creatorcontrib>Svob Strac, Dubravka</creatorcontrib><creatorcontrib>Sole, Montse</creatorcontrib><creatorcontrib>Unzeta, Mercedes</creatorcontrib><creatorcontrib>Tipton, Keith F</creatorcontrib><creatorcontrib>Mück-Šeler, Dorotea</creatorcontrib><creatorcontrib>Bolea, Irene</creatorcontrib><creatorcontrib>Della Corte, Laura</creatorcontrib><creatorcontrib>Nikolac Perkovic, Matea</creatorcontrib><creatorcontrib>Pivac, Nela</creatorcontrib><creatorcontrib>Smolders, Ilse J</creatorcontrib><creatorcontrib>Stasiak, Anna</creatorcontrib><creatorcontrib>Fogel, Wieslawa A</creatorcontrib><creatorcontrib>De Deurwaerdère, Philippe</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Giovanni, Giuseppe</au><au>Svob Strac, Dubravka</au><au>Sole, Montse</au><au>Unzeta, Mercedes</au><au>Tipton, Keith F</au><au>Mück-Šeler, Dorotea</au><au>Bolea, Irene</au><au>Della Corte, Laura</au><au>Nikolac Perkovic, Matea</au><au>Pivac, Nela</au><au>Smolders, Ilse J</au><au>Stasiak, Anna</au><au>Fogel, Wieslawa A</au><au>De Deurwaerdère, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases</atitle><jtitle>Frontiers in neuroscience</jtitle><addtitle>Front Neurosci</addtitle><date>2016-11-24</date><risdate>2016</risdate><volume>10</volume><spage>541</spage><epage>541</epage><pages>541-541</pages><issn>1662-4548</issn><issn>1662-453X</issn><eissn>1662-453X</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><notes>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience</notes><notes>Edited by: Arjan Blokland, Maastricht University, Netherlands</notes><notes>Reviewed by: Grzegorz Kreiner, Polish Academy of Sciences, Poland; John Finberg, Technion – Israel Institute of Technology, Israel</notes><abstract>The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson's disease where the pathophysiology led almost immediately to the introduction of dopamine restoring agents. Extensive neuropharmacological studies first showed that the primary target of antipsychotics, antidepressants, and anxiolytic drugs were specific components of the monoaminergic systems. Later, some dramatic side effects associated with older medicines were shown to disappear with new chemical compounds targeting the origin of the therapeutic benefit more specifically. The increased knowledge regarding the function and interaction of the monoaminergic systems in the brain resulting from
neurochemical and neurophysiological studies indicated new monoaminergic targets that could achieve the efficacy of the older medicines with fewer side-effects. Yet, this accumulated knowledge regarding monoamines did not produce valuable strategies for diseases where no monoaminergic drug has been shown to be effective. Here, we emphasize the new therapeutic and monoaminergic-based strategies for the treatment of psychiatric diseases. We will consider three main groups of diseases, based on the evidence of monoamines involvement (schizophrenia, depression, obesity), the identification of monoamines in the diseases processes (Parkinson's disease, addiction) and the prospect of the involvement of monoaminergic mechanisms (epilepsy, Alzheimer's disease, stroke). In most cases, the clinically available monoaminergic drugs induce widespread modifications of amine tone or excitability through neurobiological networks and exemplify the overlap between therapeutic approaches to psychiatric and neurological conditions. More recent developments that have resulted in improved drug specificity and responses will be discussed in this review.</abstract><cop>Switzerland</cop><pub>Frontiers Research Foundation</pub><pmid>27932945</pmid><doi>10.3389/fnins.2016.00541</doi><oa>free_for_read</oa></addata></record> |